+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)



A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 12(9): 1787-1793



KW-2083 [7-n-(p-hydroxyphenyl)-mitomycin C] is a new mitomycin C (MMC) derivative. Its myelotoxicity was compared with that of MMC by using colony-forming unit-spleen (CFU-S) from the femurs of C57BL/6 mice. As a result, it was estimated that the intensity of myelotoxicity of MMC was four times greater than that of KW-2083. Based on this data, a clinical trial of KW-2083 was conducted in 24 cases with various types of advanced solid tumors. KW-2083 was administered by i.v. injection at a dose of 40 mg/body every week. Out of 15 evaluable cases, a case of ovarian cancer showed a partial response. One case of each of ovarian cancer and gastric cancer showed minor response. However, as with mitomycin C, the dose-limiting toxicity of KW-2083 was leukopenia and thrombocytopenia. Other toxicities encountered were nausea, vomiting, anorexia, phlebitis and hepatic dysfunction. There were no cases with renal toxicity. Plasma concentration of KW-2083 was bioassayed in 3 cases who received 40 mg/body as an i.v. bolus injection. Plasma concentration-time curves fitted to a one-compartment model and half-life values averaged 27.6 min. The effective and low toxic dose schedules of KW-2083 should be investigated further.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039043685

Download citation: RISBibTeXText

PMID: 4037809


Related references

Clinical study of kw 2083 7 n p hydroxyphenyl mitomycin c a derivative of mitomycin c. Journal of Japan Society for Cancer Therapy 17(2): 536, 1982

Clinical evaluation of kw 2083 7 n p hydroxyphenyl mitomycin c. Journal of Japan Society for Cancer Therapy 17(2): 537, 1982

Pilot study of kw 2083 7 n p hydroxyphenyl mitomycin c. Journal of Japan Society for Cancer Therapy 17(2): 537, 1982

Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(6): 1290-1295, 1984

Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(12 Pt 1): 2513-2519, 1984

Antitumor spectrum of 7-N-(p-hydroxyphenyl) mitomycin C (KW 2083) in rat ascites hepatoma. Gan no Rinsho. Japan Journal of Cancer Clinics 28(2): 122-124, 1982

Pharmacokinetics of mitomycin C and its derivative (KW-2083). Gan to Kagaku Ryoho. Cancer and ChemoTherapy 9(8): 1362-1373, 1982

In vitro antitumor activity of 7-N-(p-hydroxyphenyl)-mitomycin C (KW-2083) against cultured bronchogenic carcinoma cells (PC-7). Gan no Rinsho. Japan Journal of Cancer Clinics 29(11): 1303-1305, 1983

Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay. Investigational new Drugs 3(4): 341-347, 1985

Alkylation of DNA with a mitomycin derivative, 7-N-(p-hydroxyphenyl)-mitomycin C. Reductive alkylation and preferential binding to adenine. Chemical & Pharmaceutical Bulletin 30(7): 2644-2646, 1982

Alkylation of DNA with a mitomycin derivative, 7-N-(p-hydroxyphenyl)-mitomycin C. Reductive alkylation nd preferential binding to adenine. Chemical and Pharmaceutical Bulletin 30(7): 2644-2646, 1982

Biosynthesis of mitomycin inStreptomyces caespitosus. Relationship of intracellular vitamin B12level to mitomycin synthesis and enzymatic methylation of a demethylated derivative of mitomycin. Applied Microbiology and Biotechnology 1(2): 129-145, 1975

Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Research 54(9): 2398-2403, 1994

Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo. Cancer ChemoTherapy and Pharmacology 27(2): 89-93, 1990

Sequence-specific Dna damage induced by reduced mitomycin C and 7-N-( p -hydroxyphenyl)mitomycin C. Nucleic Acids Research 12(17): 6673-6683, 1984